EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) (clinicaltrials.gov) - Sep 23, 2026 - P3 | N=11000 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2028 ➔ Dec 2026 | Trial primary completion date: Aug 2028 ➔ Dec 2026
Enrollment closed • Trial completion date • Trial primary completion date • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease
|